Jie Xue is a Senior Scientist at IGM Biosciences, Inc. since January 2023, leading teams and projects focused on cancer immunotherapy, specifically researching checkpoint inhibitors and immune modulators to create novel therapeutic biologics for breast cancer, colon cancer, and melanoma. Previously, Jie Xue held a Senior Scientist position at Binacea Pharma and served as a Project Leader and Senior Research Scientist at Hengenix Biotech, Inc. from July 2015 to January 2023. A postdoctoral researcher at Stanford University from February 2014 to June 2015, Jie Xue researched giant cell vasculitis, an autoimmune disease, and completed a PhD in Biochemistry and Molecular Biology at the University of California, Merced, where research included the development of microbicides to prevent HIV transmission. Education was pursued at Sun Yat-sen University from 2003 to 2008.
This person is not in the org chart